Skip to main content
×
×
Home

Losing participants before the trial ends erodes credibility of findings

  • Jun Xia (a1), Clive Adams (a2), Nishant Bhagat (a3), Vinaya Bhagat (a3), Paranthaman Bhoopathi (a3), Hany El-Sayeh (a3), Vanessa Pinfold (a4) and Yahya Takriti (a3)...
Abstract
Aims and Method

To estimate the proportion of attrition at which results of drug trials for people with schizophrenia lose enough credibility to become mistrusted by relevant groups of stakeholders. A piloted questionnaire was sent to 128 local clinicians, 100 relevant researchers and 104 service users and carers.

Results

We received the biggest number of responses from the service user and carer group (n=81, 76%); 43% of clinicians and 32% of researchers responded. All three groups suggested that the follow-up rate for a 12-week schizophrenia drug trial should be around 70–75% for the trial to be credible.

Clinical Implications

This survey suggests that relevant stakeholders, including researchers, fundamentally mistrust results of the majority of drug trials in schizophrenia. Adopting a more pragmatic trial design can help address this.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Losing participants before the trial ends erodes credibility of findings
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Losing participants before the trial ends erodes credibility of findings
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Losing participants before the trial ends erodes credibility of findings
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
Hide All
1 Cure, SJ, Adams, CE. Forensic trials inform the present and future. Br J Psychiatry 2000; 177: 182.
2 Thornley, B, Adams, C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998; 317: 1181–4.
3 Hollis, S, Campbell, F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999; 319: 670–4.
4 Dunn, G, Maracy, M, Tomenson, B. Estimating treatment effects from randomised clinical trials with non-compliance and loss to follow-up: the role of instrumental variable methods. Stat Methods Med Res 2005; 14: 369–95.
5 Leucht, S, Engel, RR, Bauml, J, Davis, JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF? Schizophr Bull 2007; 33: 183–91.
6 Marshall, M, Lockwood, A, Bradley, C, Adams, C, Joy, C, Fenton, M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizo-phrenia. Br J Psychiatry 2000; 176: 249–52.
7 WHO Scientific Group on Treatment of Psychiatric Disorders. Evaluation of Methods for the Treatment of Mental Disorders. World Health Organization, 1991.
8 Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23.
9 Cotton, SM, Yuen, HP, Berger, G, McGorry, P. Last observation carried forward in psychiatric research – a flawed gold standard. Aust N Z J Psychiatry 2005; 39: 622.
10 Bain, MRS, Chalmers, JWT, Brewster, DH. Routinely collected data in national and regional databases – an underused resource. J Public Health Med 1997; 19: 413–8.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Bulletin
  • ISSN: 0955-6036
  • EISSN: 1472-1473
  • URL: /core/journals/bjpsych-bulletin
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×
Type Description Title
PDF
Supplementary materials

Xia et al. supplementary material
Supplementary Material

 PDF (43 KB)
43 KB
UNKNOWN
Supplementary materials

Xia et al. supplementary material
Supplementary Material

 Unknown (424 bytes)
424 bytes

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 22 *
Loading metrics...

Abstract views

Total abstract views: 117 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 25th May 2018. This data will be updated every 24 hours.

Losing participants before the trial ends erodes credibility of findings

  • Jun Xia (a1), Clive Adams (a2), Nishant Bhagat (a3), Vinaya Bhagat (a3), Paranthaman Bhoopathi (a3), Hany El-Sayeh (a3), Vanessa Pinfold (a4) and Yahya Takriti (a3)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *